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INTRODUCTION
D-penicillamine has been known as one of the agents that
are able to induce pemphigus (1, 2). Bucillamine [N-(2-mer-
capto-2-methylpropionyl)-L-cysteine] is a thiol compound
contained two free sulfhydryl groups, whereas D-penicilla-
mine has only one sulfhydryl radical (3). While drug-induced
pemphigus was not infrequently demonstrated in associa-
tion with d-penicillamine, it has rarely been reported with
bucillamine and has never been reported in rheumatoid arthri-
tis (RA) and polymyositis (PM) overlap syndrome. Hereby,
we report a case of bucillamine-induced pemphigus vulgaris
in a patient with RA and PM overlap syndrome.
CASE REPORT
A 46-yr-old woman was referred to our rheumatology de-
partment due to polyarthralgia, and myalgia in May 2001.
Soft tissue swelling and tenderness were bilaterally noted at
the proximal interphalangeal and metacarpophalangeal joints
with morning stiffness lasting at least 1 hr. Proximal motor
weakness on upper arms and legs has insidiously developed
over three months and findings of magnetic resonance image
on both thighs were compatible with myositis. In addition,
elevated level of muscle enzymes including creatine kinase
(CK), aldolase, alanine aminotransferase (AST and ALT), and
lactate dehydrogenase was shown. Antinuclear antibody was
positive at 1:80 of speckled pattern, and 1:2,560 of cytoplas-
mic pattern. Auto-antibodies including anti-Jo-1, anti-RNP,
anti-double stranded DNA, anti-Sm, and anti-SS-A/SS-B
were absent. Level of rheumatoid factor was 3,420 IU/mL,
but level of C3 and C4 was 97.9 mg/dL (normal range 79-
152 mg/dL) and 30.8 mg/dL (normal range 16-38 mg/dL)
respectively. Chest radiograph showed pattern of interstitial
lung disease and pulmonary function test revealed signifi-
cantly decreased DLCO. She was diagnosed as RA and PM
overlap, and had been treated with prednisolone, azathioprine
and non-steroidal anti-inflammatory drug since May 2001.
Myositis became silent over time with above regimen, how-
ever she had continuous synovitis and joint pain on right knee
and small joints on both hands. Her regimen was changed
to cyclosporine and bucillamine. Twenty months later, the
skin lesions occurred. She exhibited erythematous flaccid
blisters on her chest, axillae, and back. Blisters consisted of
erythematous patches and superficial erosions with turbid
bullae suggesting pemphigus vulgaris (Fig. 1). Nikolsky’s
sign was positive. Laboratory tests showed C-reactive protein
0.831 mg/dL (normal range <0.8 mg/dL), and erythrocyte
sedimentation rate 66 mm/hr. Liver function, renal function,
CK, and electrolytes were normal. A skin biopsy revealed
intraepidermal vesicle formation with acantholysis and the
vesicle formation is suprabasal (Fig. 2). Indirect immunoflu-
orescence, performed by using serial dilutions of the patient’s
serum, demonstrated no IgG, IgA and C3 staining along
epidermis and papillary dermis. Bucillamine was discontin-
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Bucillamine-Induced Pemphigus Vulgaris in a Patient with Rheumatoid
Arthritis and Polymyositis Overlap Syndrome
Bucillamine is a disease modifying anti-rheumatic drug, structurally similar to D-peni-
cillamine. Although D-penicillamine-induced pemphigus has been not infrequently
demonstrated, pemphigus associated with bucillamine was rarely reported. We
describe a patient complicating pemphigus vulgaris after bucillamine treatment in
rheumatoid arthritis (RA) and polymyositis (PM) overlap syndrome. PM and RA
overlap syndrome was diagnosed three years ago and bucillamine was adminis-
trated for 20 months. Skin lesions including erythematous flaccid blisters on her
chest, axillae, and back were occurred and were compatible with pemphigus vul-
garis by typical pathology. Withdrawal from bucillamine and prednisolone treatment
made rapid improvement of pemphigus lesions.
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ued and the patient was placed on oral prednisolone 20 mg
daily. The skin lesions rapidly improved, and disappeared
within 2 months.
DISCUSSION
D-penicillamine and bucillamine have been used for patients
with rheumatoid arthritis as a disease modifying anti-rheu-
matic drug. D-penicillamine can cause various autoimmune
diseases including pemphigus, PM, and myasthenia gravis
(4-6). Although bucillamine has a chemical structure simi-
lar to D-penicillamine, autoimmune diseases are rarely asso-
ciated with bucillamine. Some cases of bucillamine-induced
interstitial lung disease, nephropathy, and myasthenia gravis
were described (7-9). It was reported that the incidence of
D-penicillamine-induced pemphigus was about 7% (5, 10)
and mean duration until the onset of pemphigus was 11 to
13 months (11, 12). It frequently presents as an urticarial,
annular, or moniliform erythematous prodrome. Scaly crusted
patches, vesicles, and bullae are developed subsequently (5).
The mechanism of thiol drugs-induced pemphigus is still
obscure. It has been suggested that the epidermal cell sur-
face proteins play a role as an antigen to the host through a
sulfhydryl radical and other unknown factors (1). In D-peni-
cillamine-induced pemphigus, the prevalence of IgG and
IgA antibodies directed against the intercellular region is lower
than that in spontaneously occurring pemphigus (13). It has
been shown that these antibodies might not be detected in
some cases of drug-induced pemphigus like our case (13, 14).
To date, only 2 cases of bucillamine-induced pemphigus
were reported in English literature. One was drug-induced
pemphigus foliaceus with features of pemphigus vulgaris
and the other was subcorneal pustular dermatosis-type IgA
pemphigus induced by thiol drugs (12, 14).
The discontinuation of D-penicillamine may be inadequate
in treatment because it frequently fails to stop disease pro-
gression. Initial dose of corticosteroid is typically about 0.75-
1 mg/kg/day. It has been suggested that high-dose or pulse
therapy with steroids usually clears blisters promptly. Pred-
nisolone at a lower dose of 20-30 mg/day can maintain these
patients without blistering but other adjuvant immunosup-
pressive drugs is need to achieve steroid-sparing effect or pre-
vention of relapse (15, 16). Blisters of our patient disappeared
rapidly with corticosteroid treatment and discontinuation of
bucillamine. Relapse was not found during the subsequent
6 months. 
In conclusion, bucillamine may cause pemphigus even at
a low rate therefore we have to keep in mind that skin lesions
with blisters should be carefully investigated in patients with
bucillamine treatment.
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